Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 8/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | CASP1 | P29466 | 5/20 | 0.69 |
| ▸ | CASP7 | P55210 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | ATM | Q13315 | 2/20 | 0.69 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.48 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043114 | 0.97 | KDM4E (0.64) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16940596 | 0.92 | KDM4E (0.62) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2525573 | 0.91 | KDM4E (0.84) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16940595 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14601359 | 0.84 | PKM (0.51) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12043125 | 0.84 | ALDH1A1 (0.51) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14733477 | 0.82 | ALDH1A1 (0.47) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12043094 | 0.82 | KDM4E (0.85) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12043197 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12043096 | 0.81 | MEN1 (0.81) | KDM4EALDH1A1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261404-A1 | METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE | NEURONASCENT, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-1937252-B1 | COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9539261-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539261-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150250798-A1 | Methods and Pharmaceutical Compositions For Treating Down Syndrome | NEURONASCENT, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8999972-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999972-B2 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | NEURONASCENT, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20120277218-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME | NEURONASCENT, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2480233-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME | Neuronascent, INC. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110319391-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT, INC. | 2011-12-29 | — | — | US | disclosed |
| US-20110319391-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT, INC. | 2011-12-29 | — | — | US | disclosed |
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011037962-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME | NEURONASCENT, INC; (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011037962-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME | NEURONASCENT, INC; (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2007035722-A2 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | NEURONASCENT, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277218-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME | DCX, GAP43, CHAT | KDM4E 2348/4885ALDH1A1 2328/4885KMT2A 2019/4885 |
| US-20110319391-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEUROGENESIS AND INHIBITING NEURONAL DEGENERATION | DCX, BDNF, GAP43 | KDM4E 3732/4885ALDH1A1 874/4885KMT2A 4065/4885 |
| US-20150250798-A1 | Methods and Pharmaceutical Compositions For Treating Down Syndrome | DCX, GAP43, CAMK2A | KDM4E 2217/4885ALDH1A1 3026/4885KMT2A 1363/4885 |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | KDM4E 4443/4885ALDH1A1 1544/4885KMT2A 4557/4885 |
| US-20150209371-A1 | Methods and Compositions For Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | KDM4E 3732/4885ALDH1A1 874/4885KMT2A 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.